| CCRL2 promotes antitumor T-cell immunity via amplifying TLR4-mediated immunostimulatory macrophage activation W Yin, Y Li, Y Song, J Zhang, C Wu, Y Chen, Y Miao, C Lin, Y Lin, D Yan, ... Proceedings of the National Academy of Sciences 118 (16), e2024171118, 2021 | 55 | 2021 |
| Selective synthesis of unsymmetrical ethers from different alcohols catalyzed by sodium bisulfite JL Yu, H Wang, KF Zou, JR Zhang, X Gao, DW Zhang, ZT Li Tetrahedron 69 (1), 310-315, 2013 | 35 | 2013 |
| Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from … E Felip, BC Cho, V Gutiérrez, A Alip, B Besse, S Lu, AI Spira, N Girard, ... Annals of Oncology 35 (9), 805-816, 2024 | 28 | 2024 |
| Improving lung cancer risk stratification leveraging whole transcriptome RNA sequencing and machine learning across multiple cohorts Y Choi, J Qu, S Wu, Y Hao, J Zhang, J Ning, X Yang, L Lofaro, ... BMC Medical Genomics 13, 1-15, 2020 | 19 | 2020 |
| Small molecule regulators of microRNAs identified by high-throughput screen coupled with high-throughput sequencing LD Nguyen, Z Wei, MC Silva, S Barberán-Soler, J Zhang, R Rabinovsky, ... Nature Communications 14 (1), 7575, 2023 | 18 | 2023 |
| LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early … B Besse, SH Lee, S Lu, D Stroyakovskiy, O Yazici, JRR Cid, H Hayashi, ... Annals of Oncology 35, S1245-S1246, 2024 | 7 | 2024 |
| Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A … E Felip, BC Cho, V Gutiérrez, A Alip, B Besse, S Lu, AI Spira, N Girard, ... Journal of Clinical Oncology 42 (16_suppl), 8504-8504, 2024 | 6 | 2024 |
| Pathologic and gene expression comparison of CT-screen detected and routinely detected stage I/0 lung adenocarcinoma in NCCN risk-matched cohorts. EJ Burks, J Zhang, TB Sullivan, X Shi, JM Sands, SM Regis, BJ McKee, ... Cancer treatment and research communications 29, 100486, 2021 | 5 | 2021 |
| Urine-based testing for patient selection and genomic characterization of patients with FGFR alteration-positive non–muscle-invasive bladder cancer (NMIBC) treated with TAR-210 R Li, JH Ku, AV Cabo, F Guerrero-Ramos, J Meeks, N Beeharry, M Quiroz, ... J Clin Oncol 42 (4_suppl), 2024 | 1 | 2024 |
| Quantum Mechanical-Based Stability Evaluation of Crystal Structures for HIV-Targeted Drug Cabotegravir Y Han, H Luo, Q Lu, Z Liu, J Liu, J Zhang, Z Wei, J Li Molecules 26 (23), 7178, 2021 | 1 | 2021 |
| Prognostic Impact of Oncogenic Fibroblast Growth Factor Receptor Alterations in Patients With Advanced Solid Tumors in a Real‐World Setting L Demirdjian, S Triantos, K Standish, S Thomas, Q Xia, J Zhang, ... Cancer Medicine 14 (4), e70546, 2025 | | 2025 |
| 1980P Association of PD-L1 expression with clinical response to TAR-200 in the phase IIb SunRISe-1 trial E Xylinas, C Pieczonka, JM Jacob, A Necchi, S Daneshmand, G Simone, ... Annals of Oncology 35, S1145-S1146, 2024 | | 2024 |
| 1973P Urine-based molecular testing identifies FGFR alteration-positive patients for treatment with TAR-210 F Guerrero-Ramos, JH Ku, A Vilaseca, CX Raventos, ND Shore, J Meeks, ... Annals of Oncology 35, S1143, 2024 | | 2024 |
| FGFR3 alterations (FGFRalt) in patients (pts) who develop locally advanced or metastatic urothelial cancer (mUC), and their association with tumor subtype and clinical outcomes … AO Siefker-Radtke, Y Loriot, N Matsubara, SH Park, RA Huddart, ... Journal of Clinical Oncology 42 (16_suppl), 4578-4578, 2024 | | 2024 |
| Molecular subtyping and immunohistochemistry validation identifies muscle Invasive bladder cancer subgroups with poorer overall survival J Zhang, M Feng, N Beeharry, S Thomas, R Wirtz, A Hartmann, ... Cancer Research 84 (6_Supplement), 7570-7570, 2024 | | 2024 |
| 230P Fibroblast growth factor receptor (FGFR) co-alteration (co-alt) landscape and its impact on erdafitinib (erda) response in the phase II open-label, single-arm RAGNAR trial Y Loriot, S Pant, O Witt, DA Reardon, T Doi, S Qin, J Tabernero, G Iyer, ... Annals of Oncology 34, S273, 2023 | | 2023 |
| NSCLC subtype-associated molecular and cellular alterations in the normal-appearing bronchial epithelium X Shi, J Zhang, S Callori, J Campbell, D Fine, Y Gesthalter, G Liu, X Xiao, ... Cancer Research 80 (16_Supplement), 3377-3377, 2020 | | 2020 |
| A27 Stage I Lung Adenocarcinoma Gene Expression Associated with Aggressive Histologic Features for Guiding Precision Surgery and Therapy J Zhang, E Burks, T Sullivan, J Sands, S Regis, B McKee, A McKee, ... Journal of Thoracic Oncology 15 (2), S21, 2020 | | 2020 |
| Genomic biomarker development to impact clinical management of patients at risk for lung cancer J Zhang | | 2020 |
| Altered immune response in the transcriptome of patients with lung cancer K Hijazi, J Lel, E Billatos, E Moses, CS Stevenson, MV Lorenzi, G Liu, ... Cancer Research 79 (13_Supplement), 3393-3393, 2019 | | 2019 |
